Crohn’s disease and ulcerative colitis represent distinct phenotypic forms of inflammatory bowel disease and continue to be a common cause of morbidity. The corticosteroids and the immunomodulatory drugs, which are the basis of treatment for the inflammatory bowel diseases, do not assure always satisfactory outcomes. Nutrition has been used in order to modify the inflammatory response of various chronic inflammatory diseases, including Crohn’s disease and ulcerative colitis. In the pathogenesis of inflammatory bowel diseases, the intestinal microflora and the intestinal mucosal disorders play a crucial role. Also, the release of reactive oxygen species is a significant factor of initiation and preservation of the inflammatory reaction in these diseases. The advantages of the nutritional treatment derive from the sequestration of intraluminal agents which may promote the inflammatory bowel response or, alternatively, nutrition is able to modify the immune response, reducing the uncontrolled inflammatory reaction. Furthermore, nutrition can enhance the mucosal barrier function and consists a significant source of antioxidants. This review focuses on certain nutritional components that modulate the inflammatory response of the bowel and aims to present a rational thesis regarding the use of nutritional agents in the management of inflammatory bowel diseases.

Journal Section:
Review
Keywords:
Crohnߣs disease, Oxidative stress, Ulcerative colitis
1.
Belli D, Seidman EG, Bouthillier L, Weber AM, Roy CC, Plitincx M, Beaulieu M, Morin CL: Chronic intermittent elemental diet improves growth failure in children with Crohn’s disease. Gastroenterology 1988;94:603–610.
2.
Fernandez-Banares F, Cabre E, Esteve M, Gassull MA: How effective is enteral nutrition in inducing clinical remission in active Crohn’s disease? A meta-analysis of randomized controlled trials. JPEN J Parenter Enteral Nutr 1995;19:356–364.
3.
Griffiths AM, Ohlsson A, Sherman PM, Sutherland LR: Meta-analysis of enteral nutrition as a primary treatment of active Crohn’s disease. Gastroenterology 1995;108:1056–1067.
4.
Ruemmele F, Roy CC, Levy E, Seidman EG: The role of nutrition in treating pediatric Crohn’s disease in the new millennium. Pediatr 2000;136:285–291.
5.
Seidman E: Nutritional therapy for Grahn’s disease: lessons from the Ste-Justine Hospital experience. Inflamm Bowel Dis 1997;3:49–53.
6.
Bulger EM, Helton WS: Nutrient antioxidants in gastrointestinal diseases. Gastroenterol Clin North Am 1998;27:403–419.
7.
Mates JM, Perez-Gomez C, Nunez de Castro I: Antioxidant enzymes and human diseases. Clin Biochem 1999;32:595–603.
8.
Abuja PM, Albertini R: Methods for monitoring oxidative stress, lipid peroxidation and oxidation resistance of lipoproteins. Clin Chim Acta 2001;306:1–17.
9.
Young IS, Woodside JV: Antioxidants in health and disease. J Clin Pathol 2001;54:176–186.
10.
Poulsen HE, Prieme H, Loft S: Role of oxidative DNA damage in cancer initiation and promotion. Eur J Cancer Prev 1998;7:9–16.
11.
Poulsen HE, Jensen BR, Weimann A, Jensen SA, Sorensen M, Loft S: Antioxidants, DNA damage and gene expression. Free Radic Res 2000;33(suppl):S33–S39.
12.
Miller MJS, McNeill H, Mullane KM, Caravella SJ, Clark DA: SOD prevents damage and attenuates eicosanoid release in a rabbit model of necrotizing enterocolitis. Am J Physiol 1988;255:G556–G565.
13.
Lu SC: Regulation of hepatic glutathione synthesis: current concepts and controversies. FASEB J 1999;13:1169–1183.
14.
Cotgrease IA, Gerdes RC: Recent trends in glutathione biochemistry-glutathione-protein interactions: a molecular link between oxidative stress and cell proliferation? Biochem Biophys Res Commun 1998;242:1–9.
15.
Seidman GE, Bernotti S, Levy E: Nutritional modulation of gut inflammation; in Labadarios D, Pichard C (eds): Clinical Nutrition: Early Intervention. Basel, Karger, 2002, pp 41–65.
16.
Asensi M, Sastre J, Pallardo FV, Lloret A, Lehner M, Garcia de la Asuncion J, Vina J: Ratio of reduced to oxidized glutathione as indicator of oxidative stress status and DNA damage. Methods Enzymol 1999;299:267–276.
17.
Rannem T, Ladefoged K, Hyiander E, Hegnhoj J, Staun M: Selenium depletion in patients with gastrointestinal diseases: are there any predictive factors? Scand J Gastroenterol 1998;33:1057–1061.
18.
Oz HS, Chen TS, Nagasawa H: Comparative efficacies of 2 cysteine prodrugs and a glutathione delivery agent in a colitis model. Transl Res 2007;150:122–129.
19.
Peran L, Camuesco D, Comalada M, Nieto A, Concha A, Adrio JL, Olivares M, Xaus J, Zarzuelo A, Galvez J: Lactobacillus fermentum, a probiotic capable to release glutathione, prevents colonic inflammation in the TNBS model of rat colitis. Int J Colorectal Dis 2006;21:737–746.
20.
Sido B, Hack V, Hochlehnert A, Lipps H, Herfarth C, Drooge W: Impairment of intestinal glutathione synthesis in patients with inflammatory bowel disease. Gut 1998;42:485–492.
21.
Miralles-Barrachina O, Savoye G, Belmonte-Zalar 1, Hochain P, Ducrotte P, Hecketsweiler B, Lerebours E, Dechelotte P: Low levels of glutathione in endoscopic biopsies of patients with Crohn’s colitis: the role of malnutrition. Clin Nutr 1999;18:313–317.
22.
Lih-Brody L, Powell SR, Collier KP, Reddy GM, Cerchia R, Kahn E, Weissman GS, Katz S, Floyd RA, McKinley MJ, Fisher SE, Mullin GE: Increased oxidative stress and decreased antioxidant defenses in mucosa of inflammatory bowel disease. Dig Dis Sci 1996;41:2078–2086.
23.
Wang X, Quinn PJ: The location and function of vitamin &Egr; in membranes (review). Mol Membrane Biol 2000;17:143–156.
24.
Carr A, Frei B: Toward a new recommended dietary allowance for vitamin C based on antioxidant and health effects in humans. Am J Clin Nutr 1999;69:1086–1107.
25.
Packer L, Weber SU, Rimbach G: Molecular aspects of a-tocotrienol antioxidant action and cell signaling. J Nutr 2001;131:S369–S373.
26.
Reifen R, Nur T, Ghebermeskel K, Zaiger G, Urizky R, Pines M: Vitamin A deficiency exacerbates inflammation in a rat model of colitis through activation of nuclear factor-kappaB and collagen formation. J Nutr 2002;132:2743–2747.
27.
Bitiren M, Karakilcik AZ, Zerin M, Ozardalı I, Selek S, Nazlıgül Y, Ozgonul A, Musa D, Uzunkoy A: Protective effects of selenium and vitamin E combination on experimental colitis in blood plasma and colon of rats. Biol Trace Elem Res 2010;136):87–95.
28.
Bousvaros A, Zurakowski D, Duggan C, Law T, Rifai N, Goldberg NE, Leichtner AM: Vitamins A and &Egr; serum levels in children and young adults with inflammatory bowel disease: effect of disease activity. Pediatr Gastroenterol Nutr 1998;26:129–135.
29.
Mirbagheri SA, Nezami BG, Assa S, Hajimahmoodi M: Rectal administration of d-alpha tocopherol for active ulcerative colitis: a preliminary report. World J Gastroenterol 2008;14:5990–5995.
30.
Preiser JC, Van Gossum A, Berre J, Vincent JL, Carpentier Y: Enteral feeding with a solution enriched with antioxidant vitamins A, C, and &Egr; enhances the resistance to oxidative stress. Crit Care Med 2000;28:3828–3832.
31.
Aghdassi E, Wendland BE, Steinhart AH, Wolman SL, Jeejeebhoy K, Allard JP: Antioxidant vitamin supplementation in Crohn’s disease decreases oxidative stress: a randomized controlled trial. Am J Gastroenterol 2003;98:348–353.
32.
Carr A, Frei B: Does vitamin C act as a pro-oxidant under physiological condition? FASEB J 1999;13:1007–1024.
33.
Hoffenberg EJ, Deutsch J, Smith S, Sokol RJ: Circulating antioxidant concentrations in children with inflammatory bowel disease. Am J Clin Nutr 1997;65:1482–1488.
34.
Courtois F, Sue I, Garofalo C, Ledoux M, Seidman E, Levy E: Iron-ascorbate alters the efficiency of Caco-2 cells to assemble and secrete lipoproteins. Am J Physiol 2000;279:GI2–GI9.
35.
Yu BP: Cellular defenses against damage from reactive oxygen species. Physiol Rev 1994;74:139–162.
36.
Rayman MP: The importance of selenium to human health. Lancet 2000;356:233–241.
37.
Reimund JM, Allison AC, Muller CD, Dumont S, Kenney JS, Baumann R, Duclos B, Poidron P: Antioxidants inhibit the in vitro production of inflammatory cytokines in Crohn’s disease and ulcerative colitis. Eur J Clin Invest 1998;28:145–150.
38.
Tirosh O, Levy E, Reifen R: High selenium diet protects against TNBS-induced acute inflammation, mitochondrial dysfunction, and secondary necrosis in rat colon. Nutrition 2007;23:878–886.
39.
Tran CD, Ball JM, Sundar S, Coyle P, Howarth GS: The role of zinc and metallothionein in the dextran sulfate sodium-induced colitis mouse model. Dig Dis Sci 2007;52:2113–2121.
40.
Hinks LJ, Inwards KP, Lloyd B, Clayton B: Reduced concentrations of selenium in mild Crohn’s disease. Clin Pathol 1988;41:198–201.
41.
Ringstad J, Kildebo S, Thomassen Y: Serum selenium, copper and zinc concentrations in Crohn’s disease and ulcerative colitis. Scand J Gastroenterol 1993;28:605–608.
42.
Schoelmerich J, Becher MS, Hoppe-Seyier P, Matern S, Haeussinger D, Loehle E, Koettgen E, Gerok W: Zinc and vitamin A deficiency in patients with Crohn’s disease is correlated with activity but not with localization or extent of the disease. Hepatogastroenterology 1985;32:34–38.
43.
Geerling BJ, van Houwelingen AC, Badart-Smook A, Stockbrugger RW, Brummer RJ: The relation between antioxidant status and alterations in fatty acid profile in patients with Crohn’s disease and controls. Scand J Gastroenterol 1999;34:1108–1116.
44.
Emerit J, Pelletier S, Tosoni-Verilgnue D, Mollet M: Phase II trial of copper/zinc superoxide dismutase (CuZnSOD) in treatment of Crohn’s disease. Free Radic Biol Med 1989;8:145–149.
45.
Salim A: Role of oxygen-derived free radical scavengers in the management of recurrent attacks of ulcerative colitis: a new approach. Lab Clin Med 1992;6:710–717.
46.
Geerling BJ, Badart-Smook A, van Deursen C, van Houwelingen AC, Russel MG, Stockbrugger RW, Brummer RJ: Nutritional supplementation with n–3 fatty acids and antioxidants in patients with Crohn’s disease in remission: effects on antioxidant status and fatty acid profile. Inflamm Bowel Dis 2000;6:77–84.
47.
Ojuawo A, Keith L: The serum concentrations of zinc, copper and selenium in children with inflammatory bowel disease. Cent Afr J Med 2002;48:116–119.
48.
James MJ, Gibson RA, Cleland LG: Dietary polyunsaturated fatty acids and inflammatory mediator production. Am J Clin Nutr 2000;71(suppl):S343–S348.
49.
Simopoulos AP: Omega-3 fatty acids in inflammation and autoimmune diseases. J Am Coll Nutr 2002;21:495–505.
50.
Grimble RF: Nutritional modulation of immune function. Froc Nutr Soc 2001;60:389–397.
51.
Miura S, Tsuzuki Y, Hokari R, Ishii H: Modulation of intestinal immune system by dietary fat intake: relevance to Crohn’s disease. Gastroenterol Hepatol 1998;13:1183–1190.
52.
Nagakura T, Matsuda S, Shichijyo K, Sugimoto H, Hata K: Dietary supplementation with fish oil rich in omega-3 polyunsaturated fatty acids in children with bronchial asthma. Eur Respir J 2000;16:861–865.
53.
Babcock T, Helton WS, Espat NJ: Eicosapentaenoic acid (EPA) an anti-inflammatory omega-3 fat with potential clinical applications. Nutrition 2000;16:1116–1118.
54.
Camuesco D, Gálvez J, Nieto A, Comalada M, Rodríguez-Cabezas ME, Concha A, Xaus J, Zarzuelo A: Dietary olive oil supplemented with fish oil, rich in EPA and DHA (n–3) polyunsaturated fatty acids, attenuates colonic inflammation in rats with DSS-induced colitis. J Nutr 2005;135:687–694.
55.
Hudert CA, Weylandt KH, Lu Y, Wang J, Hong S, Dignass A, Serhan CN, Kang JX: Transgenic mice rich in endogenous omega-3 fatty acids are protected from colitis. Proc Natl Acad Sci USA 2006;103:11276–11281.
56.
Breese EJ, Michie CA, Nicholls SW, Williams CB, Dolnizio P, Walker-Smith JA, MacDonald TT: The effect of treatment on lymphokine-secreting cells in the intestinal mucosa of children with Crohn’s disease. Aliment Pharmacol Ther 1995;9:547–552.
57.
Ikehata A, Hiwatashi N, Kinouchi Y, Yamazaki H, Kumagai Y, Ito K, Kayaba Y, Toyota T: Effect of intravenously infused eicosapentaenoic acid on the leukotriene generation in patients with active Crohn’s disease. Am J Clin Nutr 1992;56:938–942.
58.
McMillen MA, Ferrara A, Adrian TE, Margolis DS, Schaefer HC, Zucker KA: Cholecystokinin effect on human lymphocyte ionized calcium and mitogenesis. J Surg Res 1995;58:149–158.
59.
Luyer MD, Greve JW, Hadfoune M, Jacobs JA, Dejong CH, Buurman WA: Nutritional stimulation of cholecystokinin receptors inhibits inflammation via the vagus nerve. J Exp Med 2005;202:1023–1029.
60.
Lubbers T, de Haan JJ, Luyer MD, Verbaeys I, Hadfoune M, Dejong CH, Buurman WA, Greve JW: Cholecystokinin/cholecystokinin-1 receptor-mediated peripheral activation of the afferent vagus by enteral nutrients attenuates inflammation in rats. Ann Surg 2010;252:376–382.
61.
Shoda R, Matsueda K, Yamato S, Umeda N: Epidemiologic analysis of Crohn’s disease in Japan: Increased dietary intake of n–6 polyunsaturated fatty acids and animal protein relates to the increased incidence of Crohn’s disease in Japan. Am J Clin Nutr 1996;63:741–745.
62.
Belluzzi A, Boschi S, Brignola C, Munarini A, Cariani G, Miglio F: Polyunsaturated fatty acids and inflammatory bowel disease. Am J Clin Nutr 2000;71(suppl):S339–S342.
63.
Belluzzi A, Brignola C, Campieri M, Pera A, Boschi S, Miglioli M: Effect of an enteric-coated fish-oil preparation on relapses in Crohn’s disease. Ν Engl J Med 1996;334:1557–1560.
64.
Bassaganya-Riera J, Hontecillas R: CLA and n–3 PUFA differentially modulate clinical activity and colonic PPAR-responsive gene expression in a pig model of experimental IBD. Clin Nutr 2006;25:454–465.
65.
Tsujikawa T, Satoh J, Uda K, Ihara T, Okamoto T, Araki Y, Sasaki M, Fujiyama Y, Bamba T: Clinical importance of n–3 fatty acid-rich diet and nutritional education for the maintenance of remission in Crohn’s disease. Gastroenterol 2000;35:99–104.
66.
Uchiyama K, Nakamura M, Odahara S, Koido S, Katahira K, Shiraishi H, Ohkusa T, Fujise K, Tajiri H: n–3 polyunsaturated fatty acid diet therapy for patients with inflammatory bowel disease. Inflamm Bowel Dis 2010;16:1696–1707.
67.
Feagan BG, Sandborn WJ, Mittmann U, et al: Omega-3 free fatty acids for the maintenance of remission in Crohn disease: the EPIC Randomized Controlled Trials. JAMA 2008;299:1690–1697.
68.
Scheppach W, Sommer H, Kirchner T, Paganelli GM, Bartram P, Christl S, Richter F, Dusel G, Kasper H: Effect of butyrate enemas on the colonic mucosa in distal ulcerative colitis. Gastroenterology 1992;103:51–56.
69.
Ramos MG, Bambirra EA, Cara DC, Vieira EC, Alvarez-Leite JI: Oral administration of short- chain fatty acids reduces the intestinal mucositis caused by treatment with Ara-C in mice fed commercial or elemental diets. Nutr Cancer 1997;28:212–217.
70.
Assisi RF, GISDI Study Group: Combined butyric acid/mesalazine treatment in ulcerative colitis with mild-moderate activity: results of a multicentre pilot study. Minerva Gastroenterol Dietol 2008;54:231–238.
71.
Fernández-Bañares F, Hinojosa J, Sánchez-Lombraña JL, Navarro E, Martínez-Salmerón JF, García-Pugés A, González-Huix F, Riera J, González-Lara V, Domínguez-Abascal F, Giné JJ, Moles J, Gomollón F, Gassull MA: Randomized clinical trial of Plantago ovata seeds (dietary fiber) as compared with mesalamine in maintaining remission in ulcerative colitis. Spanish Group for the Study of Crohn’s Disease and Ulcerative Colitis (GETECCU). Am J Gastroenterol 1999;94:427–433.
72.
Tedelind S, Westberg F, Kjerrulf M, Vidal A: Anti-inflammatory properties of the short-chain fatty acids acetate and propionate: a study with relevance to inflammatory bowel disease. World J Gastroenterol 2007;13:2826–2832.
73.
Wong CW, Seow HF, Liu AH, Husband AJ, Smithers GW, Watson DL: Modulation of immune responses by bovine β-casein. Immunol Cell Biol 1996;74:323–329.
74.
Rowlands BJ, Gardiner KR: Nutritional modulation of gut inflammation. Proc Nutr Soc 1998;57:395–401.
75.
Arneho CK, Adjei AA, Harrison EK, Takeshita K, Morioka T, Arakaki Y, Ito E, Suzuki I, Kulkarni AD, Kawajiri A, Yamamoto S: Prophylactic effect of dietary glutamine supplementation in interleukin 8 and tumour necrosis factor alpha production in trinitrobenzene sulphonic acid induced colitis. Gut 1997;41:487–493.
76.
Vicario M, Amat C, Rivero M, Moretó M, Pelegrí C: Dietary glutamine affects mucosal functions in rats with mild DSS-induced colitis. J Nutr 2007;137:1931–1937.
77.
Lecleire S, Hassan A, Marion-Letellier R, Antonietti M, Savoye G, Bôle-Feysot C, Lerebours E, Ducrotté P, Déchelotte P, Coëffier M: Combined glutamine and arginine decrease proinflammatory cytokine production by biopsies from Crohn’s patients in association with changes in nuclear factor-kappaB and p38 mitogen-activated protein kinase pathways. J Nutr 2008;138:2481–2486.
78.
Kim CJ, Kovacs-Nolan JA, Yang C, Archbold T, Fan MZ, Mine Y: l-Tryptophan exhibits therapeutic function in a porcine model of dextran sodium sulfate (DSS)-induced colitis. J Nutr Biochem 2009 [in press].
79.
Faure M, Mettraux C, Moennoz D, Godin JP, Vuichoud J, Rochat F, Breuillé D, Obled C, Corthésy-Theulaz I: Specific amino acids increase mucin synthesis and microbiota in dextran sulfate sodium-treated rats. J Nutr 2006;136:1558–1564.
80.
Grimble RF, Grimble GK: Immunonutrition: role of sulfur amino acids, related amino acids, and polyamines. Nutrition 1998;14:605–610.
81.
Schrezenmeir, J, de Vrese M: Probiotics, prebiotics, and synbiotics: approaching a definition. Am J Clin Nutr 2001;73(2 suppl):S361–S364.
82.
Bengmark S: Use of some pre-, pro- and synbiotics in critically ill patients. Best Pract Res Clin Gastroenterol 2003;17:833–848.
83.
Looijer-van Langen MAC, Prajapati V, Dieleman LA: Probiotics and prebiotics as functional ingredients in inflammatory bowel disease. Nutr Today 2008;43:235–242.
84.
Rabbani, GH, Teka T, Zaman B, Majid N, Khatun M, Fuchs GJ: Clinical studies in persistent diarrhea: dietary management with green banana or pectin in Bangladeshi children. Gastroenterology 2001;121:554–560.
85.
Lindsay JO, Whelan K, Stagg AJ, Gobin P, Al-Hassi HO, Rayment N, Kamm MA, Knight SC, Forbes A: Clinical, microbiological, and immunological effects of fructo-oligosaccharide in patients with Crohn’s disease. Gut 2006;55:348–355.
86.
Welters CF, Heineman E, Thunnissen FB, van den Bogaard AE, Soeters PB, Baeten CG: Effect of dietary inulin supplementation on inflammation of pouch mucosa in patients with an ileal pouch-anal anastomosis. Dis Colon Rectum 2002;45:621–662.
87.
O’Mahony, L, McCarthy J, Kelly P, Hurley G, Luo F, Chen K, O’Sullivan GC, Kiely B, Collins GK, Shanahan F, Quigley EM: Lactobacillus and Bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 2005;128:541–551.
88.
Resta-Lenert, S, Barrett KE: Live probiotics protect intestinal epithelial cells from the effects of infection with enteroinvasive Escherichia coli (EIEC). Gut 2003;52:988–997.
89.
Madsen KL, Doyle JS, Jewell LD, Tavernini MM, Fedorak RN: Lactobacilli species prevents colitis in interleukin-10 gene-deficient mice. Gastroenterology 1999;116:1107–1114.
90.
Gionchetti P, Rizzello F, Venturi A, Brigidi P, Matteuzzi D, Bazzocchi G, Poggioli G, Miglioli M, Campieri M: Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 2000;119:305–309.
91.
Venturi A, Gionchetti Ρ, Rizzello F, Johansson R, Zucconi &Egr;, Brigidi Ρ, Matteuzzi D, Campiere M: Impact on the composition of the fecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment Pharmacol Ther 1999;13:1103–1108.
92.
Pathmakanthan S, Walsh M, Bengmark S, Willemse PJ, Bardhan K: Efficacy and tolerability treating acute distal ulcerative colitis with synbiotic enema’s: a pilot trial (abstract). Gut 2002;51:A307.
93.
Guslandi M, Mezzi G, Sorghi M, Testoni PA: Saccharomyces boulardii in maintenance treatment of Crohn’s disease. Dig Dis Sci 2000;45:1462–1464.
94.
Kruis W, Fric P, Pokrotnieks J, Lukás M, Fixa B, Kascák M, Kamm MA, Weismueller J, Beglinger C, Stolte M, Wolff C, Schulze J: Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 2004;53:1617–1623.
95.
Zocco MA, dal Verme LZ, Cremonini F, Piscaglia AC, Nista EC, Candelli M, Novi M, Rigante D, Cazzato IA, Ojetti V, Armuzzi A, Gasbarrini G, Gasbarrini A: Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 2006;23:1567–1574.
96.
Salvatore S, Heuschkel P, Tomlin S, Davies SE, Edwards S, Walker-Smith JA, French I, Murch SH: A pilot study of N-acetyl glucosamine, a nutritional substrate for glycosaminoglycan synthesis. Aliment Pharmacol Ther 2000;14:1567–1579.
97.
Butler M, Boyle JJ, Powell JJ, Playford RJ, Ghosh S: Dietary microparticles implicated in Crohn’s disease can impair macrophage phagocytic activity and act as adjuvants in the presence of bacterial stimuli. Inflamm Res 2007;56:353–361.
98.
Lomer MC, Harvey RS, Evans SM, Thompson RP, Powell JJ: Efficacy and tolerability of a low microparticle diet in a double blind, randomized, pilot study in Crohn’s disease. Eur J Gastroenterol Hepatol 2001;13:101–106.
99.
Lomer MC, Grainger SL, Ede R, Catterall AP, Greenfield SM, Cowan RE, Vicary FR, Jenkins AP, Fidler H, Harvey RS, Ellis R, McNair A, Ainley CC, Thompson RP, Powell JJ: Lack of efficacy of a reduced microparticle diet in a multi-centred trial of patients with active Crohn’s disease. Eur J Gastroenterol Hepatol 2005;17:377–384.
© 2011 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2011
You do not currently have access to this content.